Shareholders of the research company Stayble Therapeutics are invited to an extraordinary general meeting, also serving as the first meeting for liquidation purposes, on Thursday, May 7, in Gothenburg.
As previously announced, the company has prepared a balance sheet for liquidation purposes, which has been audited by the company’s auditor. The balance sheet shows that equity is less than half of the registered share capital.
The board has considered potential financing options but has concluded that the conditions to ensure continued operations are not met. The board therefore proposes that the meeting resolves on the voluntary liquidation of the company and that the company’s assets be sold to the highest…